• Explore /
  • Poster
  • / Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

Abstract Video & Slides Poster

Authors

null

Melissa Lynne Johnson

Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN

Melissa Lynne Johnson , Grace K. Dy , Hirva Mamdani , Afshin Dowlati , Adam Jacob Schoenfeld , Jose Maria Pacheco , Rachel E. Sanborn , Smitha Patiyil Menon , Linda Santiago , Yifah Yaron , Himisha Beltran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04471727

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8566)

DOI

10.1200/JCO.2022.40.16_suppl.8566

Abstract #

8566

Poster Bd #

193

Abstract Disclosures

Similar Posters

First Author: Himisha Beltran

First Author: Taofeek Kunle Owonikoko

First Author: Qingzhu Jia

First Author: Suresh S. Ramalingam